Kahn Brothers Kahn Brothers Group
Kahn Brothers Group is a value investment firm founded in the tradition of Benjamin Graham and long associated with the Kahn family of investors. The firm is known for deep-value security analysis, patience, and a multi-decade orientation to intrinsic value. Its filings are followed by classic value investors seeking Graham-and-Dodd style managers still active in public markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BP
BP
|
+$6.62M |
| 2 |
Pfizer
PFE
|
+$6.31M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$3.05M |
| 4 |
Organon & Co
OGN
|
+$2.36M |
| 5 |
FLG
Flagstar Bank National Association
FLG
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NTP
Nam Tai Property Inc.
NTP
|
+$26.5M |
| 2 |
BlackBerry
BB
|
+$9.5M |
| 3 |
Merck
MRK
|
+$1.82M |
| 4 |
Rafael Holdings
RFL
|
+$902K |
| 5 |
Seaboard Corp
SEB
|
+$390K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 35.17% |
| 2 | Healthcare | 29.89% |
| 3 | Energy | 16.69% |
| 4 | Technology | 6.19% |
| 5 | Consumer Staples | 5.68% |
Similar funds
Kahn Brothers's Q2 2021 Portfolio in Review
As of Q2 2021, Kahn Brothers held 43 positions worth $698M, up 8.1% from $646M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Trading was light in Q2 2021: portfolio turnover was 2.3%. Kahn Brothers opened 1 new position and made no exits, leaving the 43-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 35% of assets, down from 36% a quarter earlier, followed by Healthcare and Energy.
- Kahn Brothers's largest Q2 2021 buy was Organon & Co: 71,622 shares worth $2.17M.
- Kahn Brothers added most to BP in Q2 2021, an estimated $6.62M increase.
- Kahn Brothers's biggest Q2 2021 reduction was Nam Tai Property Inc., cutting an estimated $26.5M.
- Kahn Brothers's ten largest holdings make up 80% of its $698M portfolio in Q2 2021.
- Kahn Brothers opened 1 new position and closed 0 in Q2 2021.
- Kahn Brothers's portfolio value rose 8.1% quarter-over-quarter to $698M.
Based on Kahn Brothers Group's 13F filing for Q2 2021, filed 4 Aug 2021.